LuPSMA Trial : For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA

Male<br/>OnlyGender Male
Only

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

TwoPhase Two

18+Age Over 18

Prostate<br/>CancersCancer LocationProstate
Cancers

Radiotherapy | Urinary systemProstate

Trial Overview Read MoreRead more

This phase II trial is evaluating a targeted radiotherapy in men with an advanced prostate cancer that has spread to other parts of the body and is not responding to systemic treatment.
 

This trial is treating patients with prostate cancer.

This is a radiotherapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA

Other Non-Commercial Sponsor

Peter MacCallum Cancer Centre

Summary

Targeted delivery of radiotherapy (radionuclide therapy) with intravenous administration of Lutetium-177 radiolabelled to prostate specific membrane antigen (LuPSMA). - administered activity of 4-8 GBq, dose adjusted according to tumour burden, patient weight and renal function. LuPSMA administered on day 1 of a 6 week cycle. - post therapy imaging following each administration of LuPSMA with quantitative SPECT/CT with each cycle to determine radiation dose delivered to tumour and normal tissues - further cycles (up to four) will be given if post-therapy imaging demonstrates sufficient uptake to indicate further benefit. Cycles will be separated by 6 weeks

Recruiting Hospitals Read MoreRead more

Peter MacCallum Cancer Centre, Molecular Imaging
Parkville
Dr Annette Hogg
annette.hogg@petermac.org
03 9656 3744

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next